About: The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulation
Creator	Konnick, Eric
source	Elsevier; Medline; PMC
abstract	The regulatory landscape for precision oncology in the United States is complicated, with multiple governmental regulatory agencies with different scopes of jurisdiction. Several regulatory proposals have been introduced since the Food and Drug Administration released a draft guidance to regulate laboratory-developed tests in 2014. Key aspects of the most recent proposals and discussion of central arguments related to the regulation of precision oncology laboratory tests provides insight to stakeholders for future discussions related to regulation of laboratory tests.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1016/j.plabm.2020.e00172
bibo:pmid	32509953
has license	no-cc
sha1sum (hex)	daf7152ebed6a0362b6f6116c99fa6a65e6bd0c3
schema:url	https://doi.org/10.1016/j.plabm.2020.e00172
resource representing a document's title	The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulation
has PubMed Central identifier	PMC7261109
has PubMed identifier	32509953
schema:publication	Pract Lab Med
resource representing a document's body	covid:daf7152ebed6a0362b6f6116c99fa6a65e6bd0c3#body_text
is schema:about of	named entity 'UNITED STATES' named entity 'oncology' named entity 'regulation' named entity 'United States' named entity 'doi' named entity 'precision oncology' named entity 'precision oncology' named entity 'regulatory pathway' named entity 'microbial culture' named entity 'regulatory scheme' named entity 'FDA' named entity 'turnaround time' named entity 'grandfathering' named entity 'scientific studies' named entity 'precision oncology' named entity 'premarket approval' named entity 'laboratory testing' named entity 'diagnostic tests' named entity 'oncologic' named entity 'colorimetric' named entity 'precision oncology' named entity 'medical practice' named entity 'regulatory approval' named entity 'regulatory environment' named entity 'laboratory testing' named entity 'laboratory tests' named entity 'patient care' named entity 'FDA' named entity 'immunoassay' named entity 'practice guidelines' named entity 'spectroscopy' named entity 'laboratory medicine' named entity 'FDA approval' named entity 'laboratory medicine' named entity 'fluorometry' named entity 'high-risk' named entity 'high-risk' named entity 'FDA' named entity 'precision oncology' named entity 'oncology' named entity 'oncology' named entity 'centralization model' named entity 'high-risk' named entity 'laboratory tests' named entity 'FDA' named entity 'scientific principles' named entity 'patient safety' named entity 'grandfathering' named entity 'precision oncology' named entity 'laboratory tests' named entity 'fee-for-service' named entity 'approval process' named entity 'clinical care' named entity 'precision oncology' named entity 'decision-making' named entity 'patient care' named entity 'quality control' named entity 'FDA' named entity 'high-risk' named entity 'oncologic' named entity 'FDA' named entity 'patient care' named entity 'clinical care' named entity 'systematic studies' named entity 'laboratory tests' named entity 'regulatory environment' named entity 'precision oncology' named entity 'return on investment' named entity 'FDA' named entity 'practice medicine' named entity 'FDA' named entity 'regulatory pathway' named entity 'FDA' named entity 'laboratory testing' named entity 'biomarkers' named entity 'precision oncology' named entity 'Laboratory Medicine' named entity 'laboratory medicine' named entity 'overutilization' named entity 'laboratory medicine' named entity 'FDA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software